CD4 and ovarian carcinoma: An NY‐ESO‐1 peptide ESO157–170 can be recognized by HLA‐DP4‐restricted CD4 T cells and HLA‐A2‐ and A24‐restricted CD8 T cells to stimulate Th1 and Th2 CD4+ T cell responses in patients with epithelial ovarian cancer.